Clinical Trial Update: Empagliflozin for No-reflow Phenomenon in PCI for STEMI [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Empagliflozin for the no-reflow phenomenon during PCI in STEMI patients; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• No-reflow Phenomenon
• St-segment Elevation Myocardial Infarction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez | Conditions: STEMI, No-Reflow Phenomenon | Phase 2 | Status: ACTIVE_NOT_RECRUITING